Midlands delivering nearly £100 Million of COVID research
A report published on Friday 15th January 2021 celebrates how the Midlands has moved swiftly to apply the wealth of capability in its hospitals, universities and businesses to support the global effort in tackling Coronavirus.
Binding Site’s contribution to the cause – the rapid development of a world-leading antibody test - in collaboration with the University of Birmingham, is one of a number of projects highlighted within the report, titled “Mobilising Research Excellence in the Midlands to Tackle COVID-19”.
Commenting on the report, Binding Site CEO Charles de Rohan said “We are incredibly proud for our work and to have played an integral part in the Midlands’ effort as a whole. It is a testament to the strength, commitment and the collaborative will of the region’s academics, healthcare professionals and industrial partners”.
Co-authored by Midlands Innovation Health, Midlands Health Alliance and Medilink Midlands, and introduced by Sir John Peace, Chairman of Midlands Engine, the report highlights that:
• Experts in the Midlands are leading 81 new COVID-19 research programmes.
• The region is playing a crucial and integral role in the world-leading genome sequencing consortium which is identifying the strains of COVID-19 recently in the UK and internationally.
• The Midlands has used its internationally leading research excellence and clinical trials infrastructure to recruit over 50,000 patients to 46 COVID-19 clinical research trials, driving the discovery of new treatments and scientific insights.
• The region has successfully bid for £45m of funding enabling the delivery of £90m of cutting-edge COVID-19 related research.
• The region was at the forefront of the early detection of the heightened risks of COVID-19 to the country’s Black and Ethnic Minority population and bringing this to clinical attention.
For more information and to read the full report, please click here